SRA International, Inc. (NYSE: SRX) won a deal from the Department of Defense (DoD) on a re-compete “to support the receipt and scientific review of research grant applications for DoD’s Congressionally Directed Medical Research Programs (CDMRP).”
The contract would worth as much as $100 million over five years, if all options are exercised.
“CDMRP plays an important role in supporting disease-specific research, and in addressing the issues faced by our military members and their families, ” said SRA Health Programs Vice President Paul Nedzbala. “SRA fully shares this mission and we are proud that CDMRP will allow us to continue this partnership. By leveraging our scientific expertise, information technology and administrative support, SRA has been able to provide an unsurpassed level of service to CDMRP. Our team is focused on CDMRP’s mission as we make meaningful contributions to advances in important areas of biomedical research.”